GlassScriptPhysician profile
Ashley Blaske
NPI 1427314616
$7,040.35
in general payments reported to CMS, 2019-2025
37 companies · $880 in 2025
The $880 reported for 2025 was more than what 82% of Pediatric Rheumatology providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $727 · 2021: $2,534 · 2022: $1,343 · 2023: $368 · 2024: $1,188 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,995 · Education: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,995.46 |
| Education | $440.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,436.77 | 2020-2025 | Rinvoq |
| Janssen Biotech, INC. | $1,013.08 | 2020-2025 | Tremfya |
| Amgen INC. | $907.39 | 2020-2025 | Tavneos, Krystexxa, Prolia |
| Ucb, INC. | $514.86 | 2020-2024 | Cimzia |
| Pfizer INC. | $434.64 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $414.72 | 2020-2025 | Orencia |
| Lilly USA, LLC | $312.16 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $239.30 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $223.07 | 2020-2025 | |
| Glaxosmithkline, LLC. | $168.13 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $146.54 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.00 | 2022-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $133.68 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $91.36 | 2021-2022 | |
| Radius Health, INC. | $90.33 | 2020-2024 | Tymlos |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Blaske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.